Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics

@article{Belle2002EffectOP,
  title={Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics},
  author={D. Belle and C. Ernest and J. Sauer and Brian P. Smith and H. Thomasson and J. Witcher},
  journal={The Journal of Clinical Pharmacology},
  year={2002},
  volume={42}
}
The purpose of this study was to characterize the effect of potent CYP2D6 inhibition by paroxetine on atomoxetine disposition in extensive metabolizers. This was a single‐blind, two‐period, sequential study in 22 healthy individuals. In period 1, 20 mg atomoxetine bid was administered to steady state. In period 2, 20 mg paroxetine was administered qd for 17 days. On days 12 through 17, 20 mg atomoxetine bid were coadministered. Plasma pharmacokinetics of atomoxetine, 4‐hydroxyatomoxetine, and N… Expand
Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
TLDR
Paroxetine coadministration significantly affected pharmacokinetic parameters of atomxetine and its two metabolites, 4-hydroxyatomoxetines and N-desmethylatomoxetusine, in different CYP2D6 genotypes. Expand
The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite
TLDR
Multiple-dose paroxetine intake significantly influenced atomxetine and its active metabolite pharmacokinetics, causing a 5.8-fold increased exposure to atomoxettine and 1.6-fold reduced exposure to 4-hydroxyatomoxetin-O-glucuronide. Expand
Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.
  • I. Todor, A. Popa, +6 authors C. Briciu
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2016
TLDR
The effect of bupropion on CYP2D6 activity was responsible for an increased systemic exposure to atomoxetine and also for a decreased exposure to its main metabolite, 4-hydroxyatomxetine-O-glucuronide. Expand
Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
TLDR
Coadministration of potent inhibitors of CYP3A4/5 and CYP2D6, but not CyP2C9, resulted in a moderate increase in lasofoxifene exposure and no dosage adjustment should be required when lasof oxifene is coadministered with ketoconazole, fluconazoles, paroxetine or other agents that inhibit these CYP enzymes. Expand
Atomoxetine and Duloxetine: Evaluation of a Potential Pharmacokinetic Drug-Drug Interaction
Abstract Objective: The present research aimed to investigate whether a pharmacokinetic drug interaction exists between atomoxetine, a substrate of CYP2D6 and duloxetine, an enzymatic inhibitor ofExpand
The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects
TLDR
It was demonstrated that the metabolic phenotype significantly influenced atomoxetine pharmacokinetics, as PMs presented a 4.5-fold higher exposure to the parent drug and a 3.2-fold lower exposure to its metabolite in comparison to EMs. Expand
Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN-812 (Viloxazine Extended-Release) Pharmacokinetics in Healthy Adults.
TLDR
This trial investigated the pharmacokinetics and safety of SPN-812 coadministered with the potent CYP2D6 inhibitor paroxetine and reported a modest change on viloxazine AUCs with no change in Cmax. Expand
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
TLDR
This model could be utilized for identification of appropriate dosages of atomoxetine in patients with reduced CYP2D6 activity to minimize the adverse events, and to enable personalised medicine. Expand
Clinical Pharmacokinetics of Atomoxetine
TLDR
The oral bioavailability and clearance of atomoxetine are influenced by the activity of CYP2D6; nonetheless, plasma pharmacokinetic parameters are predictable in extensive and poor metaboliser patients. Expand
IN VITRO-IN VIVO EXTRAPOLATION OF CYP2D6 INACTIVATION BY PAROXETINE: PREDICTION OF NONSTATIONARY PHARMACOKINETICS AND DRUG INTERACTION MAGNITUDE
TLDR
The scaling model for mechanism-based inactivation successfully predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro data, and was in reasonable agreement with observed values of 5-, 6-, >7-, 7-, 5-, and 8-fold, respectively. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers.
TLDR
When coadministered with 50 mg/day desipramine, sertraline had significantly less pharmacokinetic interaction than paroxetine with desipramsine at the recommended starting dosages of 50mg/day and 20 mg/ day, respectively. Expand
Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
TLDR
In conclusion, paroxetine does not affect the pharmacokinetics or cardiovascular effects of terfenadine, and there was, however, a small reduction in the steadystate Cmax and AUCtau of carboxyterfenadines during coadministration with paroxETine. Expand
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
TLDR
This investigation confirms that paroxetine and fluxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxettine are moderate inhibitors of CyP2C19 and that fluVoxamine is a potent inhibitor of CYp1A2 in humans in vivo. Expand
A review of the metabolism and pharmacokinetics of paroxetine in man
TLDR
Its metabolism and pharmacokinetics are to some degree affected by the induction or inhibition of drug metabolizing enzyme(s), and drug interactions involving paroxetine are considered unlikely to be a frequent occurrence. Expand
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
TLDR
It is confirmed that desipramine is extensively metabolized via the sparteine/debrisoquine oxidation polymorphism i.e. by CYP2D6, and that paroxetine is a weak inducer of the glucuronidation of 2-OH-desipramines. Expand
Single‐Dose and Steady‐State Pharmacokinetics of Tomoxetine in Normal Subjects
TLDR
A pharmacokinetic profile of tomoxetine, a selective norepinephrine uptake inhibitor, was developed in human volunteers following single and multiple oral administrations and appeared to have a bimodal distribution. Expand
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
TLDR
These data indicate that paroxetine and fluvoxamine treatment with minimum clinically effective doses significantly inhibit CYP2D6 and CYP1A2, respectively, and have potential implications for interindividual variability in the risk for drug-drug interactions mediated by CYP 2D6 or CYP 1A2 as well as for the disposition of 17beta-estradiol and environmental procarcinogens. Expand
Dose-dependent inhibition of CYP 1 A 2 , CYP 2 C 19 and CYP 2 D 6 by citalopram , fluoxetine , fluvoxamine and paroxetine
Objectives: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptakeExpand
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
In vitro preparations of human liver microsomes were used to study the inhibiting effects of two selective serotonin reuptake inhibitor (SSRI) antidepressants, paroxetine and fluvoxamine, onExpand
The relationship between paroxetine and the sparteine oxidation polymorphism
TLDR
It is concluded that paroxetine and sparteine metabolism cosegregates, but the interphenotype difference in metabolism was less prominent at steady state than after a single dose, presumably because of saturation of thesparteine oxygenase (CYP2D6) in subjects who were extensive metabolizers. Expand
...
1
2
3
4
...